Abstract
Background
miRNAs are non-coding RNA that are recognized as biomarkers of kidney disorders. There is limited information on the differential expression of miRNA and their target genes in idiopathic nephrotic syndrome of childhood.
Methods
We enrolled patients, 2–18 years old, with steroid-sensitive nephrotic syndrome, either at onset or during relapse, and steroid-resistant disease, at diagnosis of steroid-resistance. Patients with steroid-sensitive disease were off immunosuppressive medications, while those with steroid-resistance were on therapy with prednisolone at enrollment. Controls were healthy children attending the hospital for vaccinations or for minor non-infectious, non-kidney ailments. Following RNA extraction from whole blood, differential expression of 2549 miRNAs was examined to identify differentially expressed miRNA, defined as those with absolute log2 fold change > 2 and adjusted P < 0.05. Target genes, predicted using miRNet, were compared against the genes for nephrotic syndrome in the NCBI database, and the ontology of selected genes was examined using DAVID.
Results
Comparison of miRNA expression in 36 patients and 12 controls led to the identification of 62 and 12 differentially expressed miRNA in patients with steroid-sensitive and steroid-resistant disease, respectively. Of 76 miRNAs that were differentially regulated between the two disease categories, 26 were unique to steroid-sensitive disease and 11 to steroid-resistance. Of 5955 and 2813 genes targeted by the miRNAs specific to steroid-sensitive and steroid-resistant nephrotic syndrome, respectively, 79 were relevant in context of the disease.
Conclusion
Steroid-sensitive and steroid-resistant nephrotic syndrome have distinct miRNA expression profiles, which can be examined as biomarkers and in pathogenetic pathways.
Similar content being viewed by others
References
Mahtal N, Lenoir O, Tinel C, Anglicheau D, Tharaux PL. MicroRNAs in kidney injury and disease. Nat Rev Nephrol. 2022;18:643–62.
Sun IO, Lerman LO. Urinary microRNA in kidney disease: utility and roles. Am J Physiol Renal Physiol. 2019;316:F785–93.
Tsuji K, Kitamura S, Wada J. MicroRNAs as biomarkers for nephrotic syndrome. Int J Mol Sci. 2020;22:88.
Sinha A, Bagga A, Banerjee S, Mishra K, Mehta A, Agarwal I, et al. Steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2021;58:461–81.
Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, et al. Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr. 2021;58:650–66.
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.
WHO Child growth standards. Available at child growth standards. who.int. Accessed Sep 10, 2021
Khadilkar VV, Khadilkar AV. Revised Indian Academy of Pediatrics 2015 growth charts for height, weight and body mass index for 5–18-year-old Indian children. Indian J Endocrinol Metab. 2015;19:470–6.
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140: e20171904. https://doi.org/10.1542/peds.2017-1904.
GEO accession viewer [internet]. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL8227. Accessed Jan 23, 2023
Garmire LX, Subramaniam S. Evaluation of normalization methods in mammalian microRNA-Seq data. RNA. 2012;18:1279–88.
Feng C, Wang H, Lu N, Tu XM. Log transformation: application and interpretation in biomedical research. Stat Med. 2013;32:230–9.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.
Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15:293.
Morpheus [internet]. https://software.broadinstitute.org/morpheus/. Accessed Mar 27, 2022
Nielsen F. Hierarchical clustering. In: Nielsen F, editor. Introduction to HPC with MPI for data science. Cham: Springer; 2016. p. 195–211.
Chang L, Zhou G, Soufan O, Xia J. miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020;48:W244-51.
Home—gene—NCBI [internet]. https://www.ncbi.nlm.nih.gov/gene. Accessed Jan 16, 2022
DAVID Functional annotation bioinformatics microarray analysis [internet]. https://david.ncifcrf.gov/. Accessed Jan 16, 2022
STRING: functional protein association networks [internet]. https://string-db.org/. Accessed Jan 16, 2022
R: The R project for statistical computing [internet]. https://www.r-project.org/. Accessed Apr 19, 2022
Zhang C, Zhang W, Chen HM, Liu C, Wu J, Shi S, et al. Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis. Am J Kidney Dis. 2015;65:223–32.
Kakkar D, Mallick S, Ahmad A, Goswami A, Agarwala S, Gupta AK, et al. Differential expression of miRNA in histological subtype of Wilms tumor. Pediatr Surg Int. 2022;38:257–67.
Kunwar A, Ablordeppey KK, Mireskandari A, Sheinerman K, Kiefer M, Umansky S, et al. Analytical validation of a novel microRNA panel for risk stratification of cognitive impairment. Diagnostics (Basel). 2023;13:2170.
Wang X, Liu S, Cao L, Zhang T, Yue D, Wang L, et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017;8:86592–603.
Deng X, Chu X, Wang P, Ma X, Wei C, Sun C, et al. MicroRNA-29a-3p reduces TNFα-induced endothelial dysfunction by targeting tumor necrosis factor receptor 1. Mol Ther Nucleic Acids. 2019;18:903–15.
He Q, Fang Y, Lu F, Pan J, Wang L, Gong W, et al. Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer. J Clin Lab Anal. 2019;33: e23003.
Duy J, Koehler JW, Honko AN, Minogue TD. Optimized microRNA purification from TRIzol-treated plasma. BMC Genomics. 2015;16:95. https://doi.org/10.1186/s12864-015-1299-5.
Brown RAM, Epis MR, Horsham JL, Kabir TD, Richardson KL, Leedman PJ. Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal. BMC Biotechnol. 2018;18:16.
Li Y, Kowdley KV. Method for microRNA isolation from clinical serum samples. Anal Biochem. 2012;431:69–75.
Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014;11:809–15.
Redshaw N, Wilkes T, Whale A, Cowen S, Huggett J, Foy CA. A comparison of miRNA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. Biotechniques. 2013;54:155–64.
Lipska-Ziętkiewicz BS, Schaefer F. NUP nephropathy: when defective pores cause leaky glomeruli. Am J Kidney Dis. 2019;73:890–2.
Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30:187–200.
Wang H, Yue Z, Wu J, Liu T, Mo Y, Jiang X, Sun L. The accumulation of VEGFA in the glomerular basement membrane and its relationship with podocyte injury and proteinuria in Alport syndrome. PLoS ONE. 2015;10: e0135648.
Bitzan M, Babayeva S, Vasudevan A, Goodyer P, Torban E. TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol. 2012;27:2217–26.
Hejazian SM, Rahbar SY, Bahmanpour Z, Hosseiniyan KSM, Ardalan M, Zununi VS. Dicer and Drosha expression in patients with nephrotic syndrome. BioFactors. 2020;46:645–52.
Doiron S, Paquette M, Baass A, Bollée G, Cardinal H, Bernard S. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: a cross-sectional study. Clin Biochem. 2022;109–110:51–6.
Barry A, McNulty MT, Jia X, Gupta Y, Debiec H, Luo Y, et al. Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome. Nat Commun. 2023;14:2481.
Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, et al. Transethnic, Genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome. J Am Soc Nephrol. 2018;29:2000–13.
Xu C, Li Y. Effects of miR-151-3p-mediated GLCCl1 expression on biological function in children with nephrotic syndrome. Am J Transl Res. 2021;13:1772–8.
Gee HY, Ashraf S, Wan X, Vega-Warner V, Esteve-Rudd J, Lovric S, et al. Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet. 2014;94:884.
Acknowledgements
This work was supported by funding from the Department of Biotechnology, Government of India (BT/PR11030/MED/ 30/1644/2016). The authors acknowledge the support of the All India Institute of Medical Sciences, New Delhi, and application scientists, Dr. Ratnesh Tripathi at the Agilent Technologies, Gurugram, and Dr. Gaurav Garg, at LCGC, Life Sciences LLP, New Delhi, India, in enabling the work carried out in the study.
Funding
This work was supported by Department of Biotechnology, Government of India (BT/PR11030/MED/30/1644/2016, Arvind Bagga).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors have declared that there is no conflict of interest and no competing interest.
Ethical approval
This study reports findings of research involving human participants that was conducted in compliance with ethical standards and good clinical practices, and followed written informed parental consent. All procedures performed were in accordance with the ethical standards of the institutional ethics committee (IRB approval ID: IEC/NP-334/05.09.2014; RP-10/2015) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
10157_2024_2595_MOESM1_ESM.pptx
Supplementary file1 Supplementary Figure S1. Sample electropherograms for visual assessment of RNA integrity, generated using Agilent 2100 expert software. Samples labelled as ‘pass’, based on visual assessment and RNA integrity number (RIN) >7.0, were used for differential expression of miRNAs. Sample IDs are labelled by disease (C controls; SR steroid resistant nephrotic syndrome; SS steroid sensitive nephrotic syndrome) and time-point (D diagnosis; FU follow up, i.e. remission) (PPTX 11800 KB)
10157_2024_2595_MOESM2_ESM.ppt
Supplementary file2 Supplementary Figure S2. Assessment of miRNA quality by scatter plots of normalized intensity values. Sample IDs are labelled by disease (C controls; SR steroid resistant nephrotic syndrome; SS steroid sensitive nephrotic syndrome) and time-point (D diagnosis; FU follow up, i.e. remission) (PPT 267 KB)
10157_2024_2595_MOESM3_ESM.pptx
Supplementary file3 Supplementary Figure S3. Volcano plots for the top miRNAs which were differentially expressed between patients with (a) steroid resistant nephrotic syndrome versus controls, (b) steroid sensitive nephrotic syndrome versus controls, and (c) steroid resistant versus steroid sensitive nephrotic syndrome. Top miRNAs are shown as bold black circles with leading lines, based on Euclidean distance, using threshold for log2 fold change of ±1.5 and P <0.01 (PPTX 114 KB)
10157_2024_2595_MOESM4_ESM.ppt
Supplementary file4 Supplementary Figure S4. Scatter plots of signal intensity from probes in linear models to indicate differences in miRNA expression between patients with (a) steroid resistant nephrotic syndrome versus controls, (b) steroid sensitive nephrotic syndrome versus controls, (c) steroid resistant versus steroid sensitive nephrotic syndrome, (d) steroid resistant nephrotic syndrome at diagnosis versus follow-up (remission), and (e) steroid sensitive nephrotic syndrome at diagnosis versus follow-up (remission). The X and Y axes of the scatter plot provide the log2 scaled normalized signal values for respective samples. The individual symbols, each representing an miRNA, are colored according to the signal intensity (red is high, yellow is intermediate, and blue is low). These symbols are located above or below the middle green line based on whether the respective miRNAs are over or under expressed, respectively, in Y versus X. The miRNAs whose relative expression between the two categories differs by more than two-fold fall outside the two-fold variation interval indicated by the outer diagonal green lines. The slope of the best fit regression line, shown as a black diagonal line, indicates the overall trend of miRNAs toward up or downregulation for the comparison between categories. This slope is also reflected in the coefficient of x in the equation on the top left corner (PPT 603 KB)
10157_2024_2595_MOESM5_ESM.ppt
Supplementary file5 Supplementary Figure S5. Cluster dendograms and heat maps on hierarchical clustering. Plots (a-d) show results of unsupervised clustering performed (a-b) with or (c-d) without including samples taken during follow up, to show (a, c) top 30 and (b, d) top 10 miRNAs. (e-h) Supervised clustering was similarly performed (e-f) with or (g-h) without including samples taken during follow up, to show (e, g) top 30 and (f, h) top 10 miRNAs. Sample IDs are labelled by disease (C controls; SR steroid resistant nephrotic syndrome; SS steroid sensitive nephrotic syndrome) and time-point (D diagnosis; FU follow up) (PPT 1375 KB)
10157_2024_2595_MOESM6_ESM.pptx
Supplementary file6 Supplementary Figure S6. Protein-protein interaction for genes targeted by miRNAs differentially regulated in (a) nephrotic syndrome; (b) steroid-resistant nephrotic syndrome and (c) steroid sensitive nephrotic syndrome (disconnected nodes are hidden) (PPTX 587 KB)
About this article
Cite this article
Sinha, A., Sra, M., Ahmed, A. et al. MicroRNAs in idiopathic childhood nephrotic syndrome. Clin Exp Nephrol 29, 477–484 (2025). https://doi.org/10.1007/s10157-024-02595-3
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1007/s10157-024-02595-3